MHC class II presentation of FVIII-AnnexinA5 fusion proteins internalized by antigen presenting cells

IntroductionThe development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) remains the most serious complication in the treatment of hemophilia A. While immune tolerance induction (ITI) is the standard strategy to eliminate these antibodies, it fails in approximately...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Mariarosaria Miranda, Michela Leoni, Carmen van der Zwaan, Robin van Bruggen, Chris P. M. Reutelingsperger, Karin Fijnvandraat, Arie J. Hoogendijk, Maartje van den Biggelaar, Jan Voorberg
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-09-01
Subjects:	FVIII annexin A5 antigen presentation phosphatidylserine red blood cells
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1668397/full